Profile data is unavailable for this security.
About the company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
- Revenue in USD (TTM)4.49m
- Net income in USD-10.97m
- Incorporated2017
- Employees7.00
- LocationEnsysce Biosciences Inc7946 Ivanhoe Avenue, Suite 201LA JOLLA 92037United StatesUSA
- Phone+1 (858) 263-4196
- Fax+1 (302) 636-5454
- Websitehttps://ensysce.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carisma Therapeutics Inc | 52.63m | 8.04m | 1.75m | 46.00 | 0.2222 | -- | 0.1832 | 0.0332 | 0.1881 | 0.1881 | 1.26 | -0.0208 | 2.17 | -- | -- | 1,144,174.00 | 33.09 | -26.58 | 51.48 | -30.35 | -- | -- | 15.28 | -169.12 | -- | -- | -- | -- | 31.59 | -- | 30.39 | -- | -1.99 | -- |
| Yubo International Biotech Ltd | -20.00 | -1.23m | 1.77m | 18.00 | -- | -- | -- | -- | -0.0099 | -0.0099 | 0.00 | -0.0098 | -0.00002 | -0.0005 | -- | -1.11 | -105.87 | -- | -- | -- | -- | -- | -- | -- | 0.2394 | -- | -- | -- | -99.43 | -- | -48.55 | -- | -- | -- |
| Clearmind Medicine Inc | 0.00 | -3.86m | 1.83m | -- | -- | 0.1617 | -- | -- | -30.64 | -30.64 | 0.00 | 7.54 | 0.00 | -- | -- | -- | -57.83 | -128.70 | -178.71 | -360.04 | -- | -- | -- | -- | -- | -- | 0.5987 | -- | -- | -- | 26.60 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -13.07m | 1.94m | 4.00 | -- | 0.1815 | -- | -- | -130.83 | -130.83 | 0.00 | 17.25 | 0.00 | -- | -- | 0.00 | -135.60 | -153.00 | -197.11 | -237.57 | -- | -- | -- | -- | -- | -- | 0.0031 | -- | -- | -- | 21.18 | -- | -26.93 | -- |
| Bluejay Diagnostics Inc | 0.00 | -20.07m | 1.99m | 7.00 | -- | 0.2275 | -- | -- | -134.42 | -134.42 | 0.00 | 9.01 | 0.00 | -- | -- | 0.00 | -103.46 | -70.71 | -124.04 | -82.92 | -- | -- | -- | -12,694.84 | -- | -- | 0.0028 | -- | -- | -- | -110.38 | -- | 119.51 | -- |
| Agentix Corp | 0.00 | -590.30k | 2.00m | -- | -- | -- | -- | -- | -0.0147 | -0.0147 | 0.00 | -0.0873 | 0.00 | -- | -- | -- | -735.53 | -- | -- | -- | -- | -- | -- | -- | -- | -11.76 | -- | -- | -- | -- | 3.09 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 2.10m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.11m | 30.00 | -- | -- | -- | 3.52 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| Ensysce Biosciences Inc | 4.49m | -10.97m | 2.12m | 7.00 | -- | 1.59 | -- | 0.4734 | -6.36 | -6.36 | 2.32 | 0.3783 | 0.7144 | -- | 5.02 | 641,138.60 | -174.67 | -48.70 | -270.43 | -62.66 | -- | -- | -244.49 | -501.34 | -- | -457.15 | 0.3071 | -- | 133.58 | -- | 24.83 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -3.95m | 2.14m | 2.00 | -- | 0.3551 | -- | -- | -7.30 | -7.30 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -75.76 | -86.22 | -80.46 | -561.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.15 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 4.51m | -7.66m | 2.39m | 13.00 | -- | 0.2398 | -- | 0.5312 | -4.08 | -4.08 | 1.72 | 3.42 | 0.4577 | 3.09 | 20.23 | -- | -77.84 | -87.37 | -93.34 | -107.49 | 29.73 | -- | -170.07 | -356.16 | 5.30 | -- | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.42m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -12.88m | 2.42m | 7.00 | -- | -- | -- | -- | -15.97 | -15.97 | 0.00 | -0.6301 | 0.00 | -- | -- | 0.00 | -343.49 | -- | -1,530.48 | -- | -- | -- | -- | -- | -- | -44.72 | -- | -- | -- | -- | -31.07 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Ensysce Biosciences Inc's reporting currency: US Dollar USD
13.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Dec 2025 | 149.71k | 4.12% |
| DRW Securities LLCas of 31 Dec 2025 | 98.48k | 2.71% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 86.67k | 2.39% |
| HRT Financial LPas of 31 Dec 2025 | 24.49k | 0.67% |
| Financial Plan, Inc.as of 31 Dec 2025 | 24.00k | 0.66% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 23.85k | 0.66% |
| Geode Capital Management LLCas of 31 Dec 2025 | 22.09k | 0.61% |
| Two Sigma Securities LLCas of 31 Dec 2025 | 21.61k | 0.60% |
| Williams & Novak LLCas of 31 Dec 2025 | 17.85k | 0.49% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 12.85k | 0.35% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
